Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of tocilizuMAb Versus Placebo in Polymyalgia rHeumatica With glucocORticoid dEpendence SEMAPHORE

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age older than 50 years~* Fulfilled the Chuang criteria~* And currently:~  * PMR-AS\> 10~ * Absence of signs or symptoms of other musculoskeletal or connective tissue conditions~* Able to give informed consent~* Concomitant treatments with methotrexate or hydroxy-chloroquine are permitted if stable dose since 3 months.~Exclusion Criteria:~* Clinical symptoms of giant cell arteritis~* Uncontrolled dyslipidemia, high blood pressure or cardiovascular disease~* History of major organ or haematopoietic stem cell/marrow transplant~* Clinical evidence of significant unstable or uncontrolled acute or chronic diseases not due to PMR~* Planned surgical procedure within 12 months after randomization.~* History of malignant neoplasm within the last 5 years.~* Current active infection~* Patient with elevated ALT or AST\> 5 ULN

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tocilizumab (Type: EXPERIMENTAL): 6 Intravenous infusions of tocilizumab in a dosage of 8 mg/kg (or 4 mg/kg depending on biological results as mentioned by the SPC of Tocilizumab for the rheumatoid arthritis) every 4 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): 6 Intravenous infusions of placebo (sterile sodium chloride solution) every 4 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).